Concepedia

Andrew Miller

AM

10

Publications

953

Citations

10

H-Index

2017

Active since

Affiliations

Indiana University – Purdue University Indianapolis(Current)

Indiana University School of Medicine

Segal Institute for Clinical Research

Zucker Hillside Hospital

Bristol-Myers Squibb (United States)

Andrew Miller is an author at Indiana University – Purdue University Indianapolis specializing in medicine, family medicine, and drug therapy.

ORCID

Top concepts

Publications per year

2017–2024

10

Publications

10

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia

Stephen K. Brannan, Sharon Sawchak, Andrew Miller et al. · New England Journal of Medicine · 2021 · 308 citations · Full text

Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial

Inder Kaul, Sharon Sawchak, Christoph U. Correll et al. · The Lancet · 2023 · 192 citations

, , +9

Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia

Inder Kaul, Sharon Sawchak, David P. Walling et al. · JAMA Psychiatry · 2024 · 132 citations · Full text

Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study

Colin Sauder, Luke Allen, Elizabeth Baker et al. · Translational Psychiatry · 2022 · 94 citations · Full text

Safety and tolerability of KarXT (xanomeline–trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia

Christoph U. Correll, Angel S. Angelov, Andrew Miller et al. · Schizophrenia · 2022 · 62 citations · Full text

Rows per page

1–5 of 10